Price Movement and Market Context
On 9 March 2026, Windlas Biotech closed at ₹739.20, down 2.54% from the previous close of ₹758.50. The intraday range saw a high of ₹763.40 and a low of ₹739.20, hovering near its 52-week low of ₹728.15, significantly below its 52-week high of ₹1,137.60. This decline contrasts with the broader market, where the Sensex has shown mixed returns over various periods. Notably, Windlas Biotech’s one-month return stands at -13.39%, considerably underperforming the Sensex’s -5.58% over the same timeframe. Year-to-date, the stock is down 7.02%, slightly outperforming the Sensex’s -7.39%, but the one-year return of -17.98% starkly contrasts with the Sensex’s positive 6.16% gain.
Technical Trend Analysis
The technical trend for Windlas Biotech has deteriorated from mildly bearish to outright bearish, reflecting growing negative momentum. The daily moving averages are firmly bearish, indicating that short-term price action is trending downward. This is corroborated by the Bollinger Bands, which show bearish signals on both weekly and monthly charts, suggesting increased volatility with a downward bias.
The Moving Average Convergence Divergence (MACD) presents a nuanced picture. On a weekly basis, the MACD remains mildly bullish, hinting at some underlying positive momentum in the short term. However, the monthly MACD is mildly bearish, signalling that longer-term momentum is weakening. This divergence between weekly and monthly MACD readings highlights the stock’s struggle to sustain upward momentum over extended periods.
The Relative Strength Index (RSI) offers no clear signal on either the weekly or monthly charts, indicating that the stock is neither overbought nor oversold at present. This neutral RSI reading suggests that momentum shifts may be driven more by external factors or fundamental developments rather than extreme price conditions.
Additional Technical Indicators
The Know Sure Thing (KST) indicator aligns with the MACD’s mixed signals, showing mild bullishness on the weekly chart but mild bearishness on the monthly chart. This further emphasises the short-term versus long-term momentum divergence. The Dow Theory readings reinforce the bearish outlook, with both weekly and monthly assessments mildly bearish, indicating that the stock’s price action is consistent with a downtrend.
On-Balance Volume (OBV) analysis reveals a mildly bearish trend on the weekly chart, suggesting that selling pressure is outweighing buying interest in the short term. The monthly OBV shows no clear trend, indicating a lack of strong conviction among investors over the longer term.
Momentum building strong! This Mid Cap from NBFC is on our MomentumNow radar. Other investors are catching on – will you join?
- - Building momentum strength
- - Investor interest growing
- - Limited time advantage
Mojo Score and Rating Update
Windlas Biotech’s MarketsMOJO score currently stands at 37.0, reflecting a Sell rating, downgraded from a previous Hold on 4 February 2026. This downgrade underscores the deteriorating technical and fundamental outlook for the stock. The company’s market capitalisation grade is a low 3, indicating limited market cap strength relative to peers in the Pharmaceuticals & Biotechnology sector.
Comparative Performance and Sector Context
Despite the recent weakness, Windlas Biotech has delivered impressive long-term returns, with a three-year return of 193.16% compared to the Sensex’s 31.04%. However, this strong historical performance has not insulated the stock from recent technical deterioration. The Pharmaceuticals & Biotechnology sector continues to face headwinds, including regulatory challenges and pricing pressures, which may be contributing to the stock’s bearish momentum.
Investor Implications and Outlook
For investors, the current technical signals suggest caution. The bearish moving averages and Bollinger Bands indicate that the stock may face further downside risk in the near term. The mixed MACD and KST readings imply that any short-term rallies could be limited or short-lived. The neutral RSI suggests that the stock is not yet oversold, leaving room for additional declines before a potential technical rebound.
Given the downgrade to a Sell rating and the weak market cap grade, investors should carefully assess their exposure to Windlas Biotech. Monitoring volume trends and broader sector developments will be crucial in determining whether the stock can stabilise or if further technical deterioration is likely.
Windlas Biotech Ltd or something better? Our SwitchER feature analyzes this small-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Summary and Final Assessment
Windlas Biotech Ltd’s technical parameters have shifted decisively towards a bearish stance, with multiple indicators signalling increased downside risk. The stock’s price momentum is weakening, as evidenced by bearish moving averages, Bollinger Bands, and Dow Theory signals. While short-term indicators such as weekly MACD and KST show mild bullishness, these are overshadowed by longer-term bearish trends and a recent downgrade in the Mojo Grade to Sell.
Investors should weigh the stock’s strong historical returns against the current technical challenges and sector headwinds. A cautious approach is warranted until clearer signs of a sustained technical recovery emerge. Monitoring key support levels near the 52-week low of ₹728.15 and observing volume trends will be critical in assessing the stock’s next directional move.
Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →
